Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%

October 6, 2026 updated by: Eye Research Associates, LLC

A Clinical Evaluation of Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%

Dry Eye Disease is a multifaceted condition which has symptoms such as eye dryness, burning, and stinging sensation in the eyes. As well as clinical diagnosis such as a decreased ability to create tear film. Despite improvements in Contact Lenses (CL) DED still is responsible for a large percentage of CL dropouts due to discomfort. Thus, the purpose of this study is to determine if acoltremon 0.003% can improve the frequency and severity of DED symptoms in CL wearers.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

This 1 month 3 visit, single arm open label study aims to determine if acoltremon 0.003% can improve the frequency and severity of Dry Eye Disease (DED) symptoms in CL wearers. DED is a multifactorial condition that can cause stinging, burning sensation or dry eyes. It can also have clinically significant findings such as decreased tear production (aqueous-deficient DED) or increased tear evaporation (evaporative DED). Conditions like this often lead to discomfort, and thus individuals to drop out of wearing contact lenses. With nearly 20% of CL dropouts annually being due to discomfort.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Chris Lievens, OD, PhD
  • Phone Number: 901-481-5699
  • Email: clievens@sco.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • • Adult subjects who are ≥18 years of age.

    • Best corrected CL visual acuity of 0.1 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes (Snellen equivalent 20/25).
    • Willing to wear a new pair of CLs to the baseline study visit.
    • Daily, soft, frequent replacement CL wearer (daily disposable, bi-weekly, or monthly CLs).
    • An Eye Dryness VAS score of ≥40.
    • CLDEQ-8 scores (CLDEQ-8 scores ≥12).
    • A score of >7 dots on the Lexitas NEI staining scale (grade 1 in a single sector on the 5-sector scale).
    • Habitual wearers of soft CLs for a minimum of 5 days per week for 6 hours or more per day during the month prior to enrollment.
    • Willing to maintain habitual soft CL wear of a minimum of 5 days per week for 6 or more hours per day for the 1 month duration of the study.
    • Habitual CLs have an acceptable fit (good centration, movement, and coverage

Exclusion Criteria:

  • Any history of acoltremon 0.003% use.
  • Are currently an overnight CL wearer.
  • Are currently hard or scleral CL wearers.
  • Have known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).
  • Have a history of ocular surgery within the past 12 months.
  • Have a history of viral eye disease that may confound study results.
  • Have a history of severe ocular trauma, active ocular infection or inflammation.
  • Have ever used isotretinoin-derivates (e.g., Accutane).
  • Are currently taking ocular medications (including topical glaucoma medication) or plan to during the study.
  • Have had a physical meibomian gland treatment withing 1 month of enrollment (iLux, Lipiflow, Radio Frequency and IPL with manual expressions, microblepharoexfoliation etc.).
  • Have used a prescription DED medication in the last 1 month.
  • Unwilling to agree to discontinue artificial tear use the day before enrollment and throughout the study.
  • Have a condition or in a situation, which in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation.
  • Are pregnant or breast feeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: acoltremon 0.003%

participants will be provided with acoltremon 0.003% and instructed to use it twice a day.

Acoltremon 0.003% (TRYPTYR; Alcon Laboratories; Fort Worth, TX, USA) was recently approved by the US Food and Drug Administration (FDA) as the first transient receptor potential melastatin (TRPM8) agonist for the treatment of DED. Acoltremon 0.003% is dosed twice a day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Eye Dryness Score (VAS) at 4 weeks compared to baseline
Time Frame: 1 month

participants will be asked to evaluate their eye dryness using a VAS scale with higher numbers indicating greater comfort.

1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Eye Dryness Score (VAS) at 2 weeks compared to baseline
Time Frame: two weeks

participants will be asked to complete an eye dryness visual analog scale with higher numbers indicating greater comfort

two weeks
CL End of day comfort VAS
Time Frame: 4 weeks

participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort

4 weeks
CL End of day comfort VAS
Time Frame: 2 weeks

participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort

2 weeks
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Time Frame: 1 month

participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort

1 month
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Time Frame: 2 weeks

participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort

2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 10, 2026

Primary Completion (Estimated)

February 14, 2027

Study Completion (Estimated)

February 21, 2027

Study Registration Dates

First Submitted

September 24, 2026

First Submitted That Met QC Criteria

September 24, 2026

First Posted (Actual)

September 30, 2026

Study Record Updates

Last Update Posted (Actual)

October 8, 2026

Last Update Submitted That Met QC Criteria

October 6, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRB000673-Acoltremon dry eye

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

An abstract describing the primary outcome will be submitted for ARVO 2027, and a manuscript on the same topic will be submitted to Contact Lens & Anterior Eye or similar publication. An abstract related to the Likert survey results will be submitted to Optometry's Meeting 2027

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe